![A woman walking confidently down a city street with two tan-colored wolves, one on each side of her, all facing forward. The text next to her reads "For your patients with SSTR+ GEP-NETs, START STRONG WITH LUTATHERA. Lutathera has practice-changing evidence for your patients who are newly diagnosed or at SSA progression. Not an actual patient."](https://usim.beprod.lutathera-hcp.com/sites/lutathera_hcp_com/files/styles/hero_full_width_width_2560/public/2024-05/lutathera-gep-nets-start-strong-2050.png?itok=ReCfqi2a)
NETTER-2 is a phase 3, randomized, open-label, active comparator, multicenter study of the efficacy of LUTATHERA with 30 mg octreotide LAR (n=151) vs 60 mg octreotide LAR (n=75) in patients with newly diagnosed, well-differentiated, grade 2 or 3 advanced SSTR+ GEP-NETs. The primary end point of the study was centrally assessed PFS. The median PFS in the LUTATHERA arm was 22.8 months (95% CI, 19.4-NE) vs 8.5 months (95% CI, 7.7-13.8) in the control arm.1,4*
NETTER-1 was a pivotal, phase 3, randomized, multicenter, open-label study of LUTATHERA with 30 mg octreotide LAR (n=116) vs 60 mg octreotide LAR (n=113) in patients with locally advanced, inoperable, or metastatic grade 1 or 2 SSTR+ GEP-NETs after progression on an SSA. The primary end point of the study was centrally assessed PFS. The median PFS in the LUTATHERA arm was not reached at primary analysis (95% CI, 18.4-NE) vs 8.5 months (95% CI, 6.0-9.1) in the control arm.2,3,5*
*Defined as the time from randomization to first documented progression (centrally assessed according to RECIST v1.1) or death due to any cause.1